人工低血糖症可能在接受佩格菲尔格拉斯蒂姆辅助化疗的软组织肉瘤患者中很常见
Tomoki Nakamura1, Kunihiro Asanuma1, Tomohito Hagi1
1Department of Orthopedic Surgery, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507, Japan.
概括
人工低血糖症可能发生在接受格菲尔格拉斯蒂姆的软组织肉瘤患者中. 高白细胞计数与低葡萄糖水平相关,这表明监测是关键.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 临床化学 临床化学
背景情况:
- 接受佩格菲尔格拉斯蒂姆治疗的软组织肉瘤 (STS) 患者可能会出现人工低血糖症.
- 这项研究调查了这些患者的白细胞计数和禁食血糖之间的关系.
研究的目的:
- 确定接受佩格菲尔格拉斯蒂姆治疗的STS患者白细胞计数和人工低血糖之间的相关性.
- 在这个患者群体中提供管理明显低血糖症的指导.
主要方法:
- 19 STS患者在佩格菲尔格拉斯蒂姆给药后被监测白细胞计数和禁食血糖水平.
- 血液样本在pegfilgrastim注射后一周内进行分析,重点是2天内采集的样本.
- 患者没有糖尿病病史.
主要成果:
- 在13名患者 (38个样本) 观察到低血糖,没有任何症状.
- 在患有低血糖症的样本中发现白细胞数量显著增加 (中位数为29415对3420).
- 白细胞计数与禁食血糖有很强的负相关性 (r:0.786,p < 0.001).
结论:
- 接受佩格菲尔格拉斯蒂姆治疗的STS患者无症状低血糖症与白细胞计数升高有关.
- 医生应该考虑监测葡萄糖水平和白细胞趋势,而不是进行侵入性低血糖调查.
- 允许葡萄糖水平与中性粒细胞的最低水平正常化,可以防止不必要的手术.
相关概念视频
Hypoglycemia and Glucagon
306
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
219
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
219
Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
SBAR II: Application of SBAR
4.5K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.5K
Oral Hypoglycemic Agents: Sulfonylureas
250
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
250


